Envista Holdings stock performance snapshot

Envista Holdings (NVST) has seen its stock decline around 1% over the past day and about 12% over the past week, with the move extending to roughly 11% over the past month.

Over the past 3 months, the stock is down about 17%. The year-to-date return remains positive at roughly 10%, and the 1-year total return is about 33%.

The recent slide, including a 1-week share price return of down 11.64% and a 3-month share price return of down 16.86%, contrasts with a 1-year total shareholder return of 33.41%. This suggests fading short term momentum after a stronger run.

If you are reassessing your watchlist in light of Envista's recent swings, it can be helpful to scan other health related opportunities through Simply Wall St's 33 healthcare AI stocks

With Envista trading at $23.92 and an implied discount to both analyst targets and intrinsic estimates, the key question is whether the current price underestimates its dental platform or if the market is already pricing in future growth.

Most Popular Narrative: 16.6% Undervalued

Envista's most followed narrative puts fair value at $28.69 per share versus the last close at $23.92, framing the recent pullback against a higher long term anchor.

Increasing R&D investment (up 14% year-over-year) and successful launches of digital and AI-driven products (e.g., DTX Studio Clinic with AI, DEXIS CDCTs, Spark product line) enhance Envista's ability to capitalize on growing demand for digital dentistry, supporting both future revenue growth and gross margin expansion.

Curious what kind of revenue path, margin lift, and future earnings multiple are baked into that $28.69 figure? The core narrative leans on steady top line progress, rising profitability and a rich earnings multiple that sits well above the broader medical equipment group.

Result: Fair Value of $28.69 (UNDERVALUED)

However, there are still clear swing factors, including Chinese volume based procurement pressure on implants and orthodontics, and tariff or FX hits that could quickly dent margins.

Another View: Earnings Multiple Sends A Different Signal

While the SWS DCF model points to value at $38.86 per share, Envista currently trades on a P/E of 57.5x compared with a fair ratio of 29.7x, the US Medical Equipment industry at 24.1x and peers at 47.6x. That gap suggests investors are paying a high price for the growth story, so how comfortable are you with that premium?

Next Steps

Given the mixed signals in recent pricing and valuation, it makes sense to look at the underlying data yourself and decide if the optimism holds up. To see what is driving that optimism and assess the upside for yourself, take a closer look at the 4 key rewards

Looking for more investment ideas?

If Envista has caught your attention, do not stop here. Broaden your opportunity set with a few focused stock lists that can sharpen your next move.

• Scan for potential mispriced opportunities by reviewing companies in the 46 high quality undervalued stocks that pair quality fundamentals with appealing valuations.
• Target income-focused opportunities by checking out the 14 dividend fortresses that may help you build a steadier stream of payouts.
• Prioritize resilience by assessing companies in the 68 resilient stocks with low risk scores that score well on financial strength and lower risk profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.